Immucell Story

<div class='circular--portrait' style='background:#FF01C9;color: #E6E6FA;font-size:4em;'>IM</div>
ICCC -- USA Stock  

USD 10.95  1.60  17.11%

It appears ImmuCell will continue to recover much faster as its share price surged up 25.50% today. The entity current daily volatility is 4.09 percent, with a beta of 0.3 and an alpha of 0.77 over DOW. As many millenniums are trying to avoid pharmaceutical products, it makes sense to go over ImmuCell a little further and try to understand its current market patterns. We will evaluate why recent ImmuCell price moves suggest a bounce in March.
Published over a month ago
View all stories for Immucell | View All Stories
Is ImmuCell (NASDAQ:ICCC) stock way too aggressive for baby boomers?
ImmuCell currently holds roughly 5.91 M in cash with 1.11 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82. We provide advice to complement the regular expert consensus on ImmuCell. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Investing in Immucell, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Immucell along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Immucell's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Immucell in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immucell. Your research has to be compared to or analyzed against Immucell's peers to derive any actionable benefits. When done correctly, Immucell's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Immucell Cp.

How important is Immucell's Liquidity

Immucell financial leverage refers to using borrowed capital as a funding source to finance Immucell Cp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immucell financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Immucell's total debt and its cash.

How Immucell utilizes its cash?

To perform a cash flow analysis of Immucell, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Immucell is receiving and how much cash it distributes out in a given period. The Immucell cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Immucell Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 268,538

Immucell Correlation with Peers

Investors in Immucell can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Immucell Cp. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Immucell and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Immucell is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Immucell for more details

Disposition of 5258 shares by Bobbi Brockmann of ImmuCell subject to Rule 16b-3

Legal trades by Immucell insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
ImmuCell insider trading alert for disposition of incentive stock options (right to buy) by Bobbi Brockmann, the corporate stakeholder, on 11th of December 2020. This event was filed by Immucell Corp with SEC on 2020-12-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Immucell valued fairly by the market?

ImmuCell is somewhat reliable given 1 month investment horizon. ImmuCell holds Efficiency (Sharpe) Ratio of 0.25, which attests that the entity had 0.25% of return per unit of risk over the last month. Our standpoint towards determining the risk of a stock is to use both market data as well as company specific technical data. We were able to break down twenty-one different technical indicators, which can help you to evaluate if expected returns of 1.02% are justified by taking the suggested risk. Use ImmuCell Downside Deviation of 2.64, risk adjusted performance of 0.1903, and Market Risk Adjusted Performance of 2.79 to evaluate company specific risk that cannot be diversified away.
DRNA
EDIT
NK
DYAI
EARS
DRNA
0.150.38-0.520.54
DRNA
EDIT
0.150.83-0.730.66
EDIT
NK
0.380.83-0.710.67
NK
DYAI
-0.52-0.73-0.71-0.68
DYAI
EARS
0.540.660.67-0.68
EARS
DRNA
EDIT
NK
DYAI
EARS
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will ImmuCell current rise continue?

Current semi variance is at 4.14. ImmuCell currently demonstrates below-verage downside deviation. It has Information Ratio of 0.16 and Jensen Alpha of 0.77. However, we do advice investors to further question ImmuCell expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Conclusion on ImmuCell

Whereas some firms within the biotechnology industry are still a little expensive, even after the recent corrections, ImmuCell may offer a potential longer-term growth to investors. All things considered, as of the 30th of January 2021, our analysis shows that ImmuCell moves slightly opposite to the market. The company is undervalued and projects low chance of bankruptcy for the next 2 years. Our ongoing 30 days recommendation on the company is Strong Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Immucell Cp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com